Update: Investigation of bioterrorism-related anthrax, 2001.
This report updates the investigation of bioterrorism-related anthrax and the provision of antimicrobial prophylaxis to exposed persons and highlights CDC assistance to other countries investigating cases of bioterrorism-related anthrax. Since November 7, 2001, CDC and state and local public health agencies have identified no new cases of bioterrorism-related anthrax. As of November 14, a total of 22 cases of anthrax has met the CDC case definition; 10 were confirmed inhalational anthrax, and 12 (seven confirmed and five suspected) were cutaneous anthrax. Investigation of a case of inhalational anthrax in a hospital stock room worker aged 61 years in New York City (NYC) found no evidence of anthrax contamination at the work site or home; the source of exposure is unknown. Environmental clean-up of contaminated facilities continues, and surveillance for newcases of bioterrorism-related anthrax is ongoing in Delaware (DE), District of Columbia (DC), Florida (FL), Maryland (MD), New Jersey (NJ), NYC, Pennsylvania (PA), Virginia (VA), and other states.
D000881:Anthrax / Q000453:epidemiology / Q000517:prevention & control; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D001408:Bacillus anthracis; D023482:Bioterrorism; D002487:Centers for Disease Control and Prevention, U.S.; D004781:Environmental Exposure; D014943:Global Health; D006801:Humans; D016273:Occupational Exposure; D015980:Public Health Practice; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000517:prevention & control; D017192:Skin Diseases, Bacterial / Q000453:epidemiology / Q000517:prevention & control; D013171:Spores, Bacterial; D014481:United States / Q000453:epidemiology
D000900:Anti-Bacterial Agents